Servier was proud to sponsor and attend the annual Becker Education & Engagement Day alongside the #BeckerMuscularDystrophy community. It was great to learn from the experiences of patients, hear the latest research, and strengthen connections across the Becker community.

We’re pleased to announce that the first patients have been dosed in the pivotal Phase 2 EMBLEM-1 cohort of a Phase 1/2 study evaluating our investigational antibody drug conjugate in patients with aggressive adenoid cystic carcinoma (ACC). Read more: lnkd.in/gt6RWCK9

We believe the next generation of breakthrough medicines will be realized through strong partnerships. That is why we are excited for Servier Partnering Day in South San Francisco, CA, hosted in collaboration with @Biocom California. To register, visit: lnkd.in/g4arYDxc

We are happy to share that #Servier has been named a finalist in this year's @Citeline Biotech Awards in the Excellence in Rare Disease Drug Development category for our efforts in advancing research for children with KCNT1-DEE. Learn more: lnkd.in/gzMn_3G2

We're proud to share that Servier has been named one of the 2026 Best Workplaces in BioPharma. This recognition reflects the culture our employees have built together, one rooted in purpose, teamwork, and a shared commitment to patients. Learn more: ttps://lnkd.in/guUcneiz

This #BeckerAwarenessWeek, we're highlighting resources that can help the #Becker community learn more about the disease, connect through shared experiences, and access support. Explore the resources: lnkd.in/e54DEHAg

Childhood Cancer Awareness Month is coming to an end, but the work cannot pause here. Servier was honored to sponsor the @ACSCAN Pediatric Cancer Landscape Report, developed in partnership with the Alliance for Childhood Cancer. Read the report here: lnkd.in/gwku9zmh

Next month, Servier is proud to sponsor and attend Becker Education & Engagement Day to learn from and connect with the Becker muscular dystrophy community. We look forward to joining the conversation! Learn more and register here: lnkd.in/e4H3d2nF

At LSX Congress USA, Jerome Klein reflected on Servier's partnership-first approach and how it continues to shape our growth as we build a rare neurology franchise. Thank you to LSX for bringing together leaders to explore new opportunities to advance innovation for patients.

Servier was proud to attend the @theABTA Conference. During a panel, Christelle Chacar, MD, shared insights on the challenges – and opportunities – of advancing brain tumor care. We're grateful to ABTA for creating opportunities to connect with the brain tumor community.

At the 50th anniversary #APHON conference, Torrey Arlon joined fellow hematology/oncology nurses to reflect on nearly a decade in pediatric hematology/oncology nursing. We’re grateful to nurses everywhere for the expertise and compassion they bring to patients every day.

At #FiercePharmaWeek, Kelly Schlemm, VP & Head of Corporate Affairs, moderated a panel discussion exploring how organizations can lead stakeholders through M&A, pipeline shifts & organizational transformation. Thank you to Kelly & the panelists for sharing their perspectives!

This #ChildhoodCancerAwarenessMonth, we’re honored to share Payton’s story. Her journey is a powerful reminder of the strength demonstrated by so many young people affected by cancer. Note: Payton is not an employee of Servier. Her story is shared for awareness purposes only.

In recognition of #ChildhoodCancerAwarenessMonth & #BloodCancerAwarenessMonth, employees came together to show their support for those impacted by childhood and blood cancer. Our commitment to patients extends far beyond a single month. Every month matters when facing cancer.

#AcuteLymphoblasticLeukemia (ALL) is a rare, rapidly progressing blood cancer that starts in the bone marrow and spreads into the blood. Learn more about ALL, including potential risk factors, symptoms and approaches to treatment. For more information: lnkd.in/gB-DV7rA

This #BloodCancerAwarenessMonth, we recognize the strength & resilience of the blood cancer community. We're committed to advancing possibilities for patients and helping build a future where more people can look ahead with confidence & hope. Learn more: lnkd.in/gB-DV7rA

Join us on September 23 in Washington, D.C. to explore how stronger collaboration between the U.S. and France can help accelerate innovation, address barriers to care, and improve the lives of patients affected by rare diseases. Register here: luma.com/n1ush3bm

On #WorldDuchenneAwarenessDay we stand alongside the Duchenne community and remain committed to helping build a better future for those affected by this disease. Learn more about our efforts here: lnkd.in/g2pvPdKD

We're attending #EEC2026 to engage in meaningful dialogue around the latest scientific advancements and innovative approaches to the treatment & management of #epilepsy. We look forward to connecting with the epilepsy community and contributing to these important conversations.

September is #ChildhoodCancerAwarenessMonth. But for children and families affected by cancer, every month matters. At Servier, commitment to the pediatric cancer community is carried forward year-round. Hear from colleagues across our organization about their "why."